semaglutide
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials
June 28, 2021Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes
Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …
Novo’s oral semaglutide tops Jardiance and Victoza in two type 2 diabetes trials
June 10, 2019Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …
Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3
November 26, 2018Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide
Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …
Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study
August 21, 2018Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …
Novo’s oral semaglutide beats Victoza and Januvia in diabetes
June 21, 2018Research and Development Januvia, MSD, Novo Nordisk, Victoza, pharma, semaglutide
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue …
Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial
February 23, 2018Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …
Novo’s diabetes treatment semaglutide gets unanimous FDA backing
October 19, 2017Sales and Marketing Novo Nordisk, diabetes, semaglutide
Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …
Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk
September 16, 2016Medical Communications Novo Nordisk, diabetes, semaglutide
Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …
Novo Nordisk pushes forward with new diabetes drug trial
July 13, 2015Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes
Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …
